Table 1.
MEDIATORS OF NEOVASCULARIZATION | ||
---|---|---|
Factor | Role in neovascularization | References |
VEGF | Stimulates development of blood vessels | (1, 2, 15–27) |
sFlT-1 | Endogenous VEGF antagonist | (25, 26) |
VEGF Polymorphisms | Increase circulating VEGF activity | (16, 19, 29–31) |
eNOS and NO | eNOS regulates NOS production, which consequently regulates endothelial progenitor cell differentiation, apoptosis, and differentiation at vessel formation sites | (1, 15, 33, 37–44) |
IGF-1 | Promotes growth throughout the body | (2, 45–50) |
Interferon | PAPP-a inhibitor | (48, 50) |
IGFBP-3 | Major regulator of free IGF-1 levels | (28, 51–53) |
Angiopoietins | Regulators of neovascularization, influenced by VEGF | (13, 18, 54–57) |
Tie2 and soluble Tie2 receptors | Promotes endothelial cell survival and maturazion and vessel stabilization | (13, 18, 55) |
TGF-β | Regulator of cell growth, differentiation, migration, and extracellular matrix protein production | (13, 22, 46, 58–71) |
Superoxide dismutase | Prevent cell injury by catalyzing reduction of superoxide radicals | (72–79) |
Vitamin A | Influences endothelial cell proliferation required for angiogenesis | (80–86) |
Trombospondin-1 | Ca binding extracellular glycoproteins with anti-angiogenic properties that regulate cell-cell and cell-matrix interactions | (13–87) |
PEDF | Neuroprotective growth factor with anti-angiogenic properties | (88–98) |
Abbreviations used in Table are as noted in text.